Accuray reports Q2 EPS 3c, consensus (4c)

Reports Q2 revenue $116.2M, consensus $110.36M. “Our strong Q2 performance reflects outstanding execution of our strategies of advancing radiotherapy care, expanding patient access and improving margin performance of the business. We continue to see growing demand for our solutions from our increased commercial presence particularly in fast-growing emerging markets evidenced by the strong momentum in Tomo C System deliveries this quarter, as well as breakthrough wins of our new Helix system, following CE mark in the first fiscal quarter,” said Suzanne Winter, president and CEO of Accuray (ARAY). “Our continued innovation in product and service offerings are helping close the gaps to cancer care and expand on the curative power of radiation therapy to improve as many lives as possible.”